Forest potentially boosts GI portfolio with $1bn buy of Furiex
Just two months after Actavis PLC announced it bought Forest Laboratories Inc. for $23.9bn, Forest is making an acquisition itself, taking over publicly traded biotech Furiex Pharmaceuticals Inc. for $1bn up front in cash, or $95/share (a 20% premium).
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.